PROMETHEUSBİLGİ ŞEHRİParşömen atölyesine gir →

GÜNÜN PARŞÖMENİ · 1 EKİM 2026 · GEN TEDAVİSİ VE KİSTİK FİBROZ

Tasarlanmış tRNA hatalı dur sinyallerinin aşılmasına yardım ediyor

Engineered tRNA Helps Cells Read Past Faulty Stop Signals

C1 · 4 dakikalık okuma · Kaynak: National Institutes of Health, 29 Eylül 2026

Metin

About one in ten cystic fibrosis cases involves a nonsense mutation that inserts a premature stop signal into the instructions for making CFTR protein. Current medicines do not adequately help this group. An NIH-funded team engineered suppressor transfer RNA, or sup-tRNA, to recognise a faulty signal and insert the missing amino acid so protein production could continue. A chemical modification made the molecule more active and stable while reducing immune activation. Researchers then screened roughly 1,000 lipids to identify a nanoparticle carrier capable of delivering the cargo without a virus. In mice, an inhaled formulation reached lung epithelial cells and increased full-length CFTR production. In intestinal organoids derived from a patient, sup-tRNA combined with the approved drug Trikafta significantly improved CFTR function, although neither treatment worked alone in that model. The approach does not alter DNA, but these preclinical results still require human safety and effectiveness studies.

Özet ve soru Prometheus’a aittir. Haberin tamamı: National Institutes of Health ↗

Beş ifade

  • nonsense mutation: erken dur sinyali oluşturan anlamsız mutasyon
  • premature stop signal: erken dur sinyali
  • suppressor transfer RNA: baskılayıcı taşıyıcı RNA
  • immune activation: bağışıklık sisteminin etkinleşmesi
  • preclinical finding: klinik öncesi bulgu

YDS mini sorusu

Why was the organoid result with sup-tRNA and Trikafta especially important?

  1. It showed that Trikafta permanently corrected the patient’s DNA without assistance from another treatment.
  2. It proved that lipid nanoparticles work only in intestinal tissue and cannot reach cells in the lungs.
  3. It demonstrated that every cystic fibrosis mutation responds equally well to one standard drug regimen.
  4. It established the treatment as safe and effective in large groups of people with cystic fibrosis.
  5. It revealed a functional improvement from the combination when neither treatment was effective alone in that model.
Cevabı ve açıklamasını göster

Doğru cevap: E

Hasta kaynaklı bağırsak organoidinde sup-tRNA ya da Trikafta tek başına CFTR işlevini iyileştirmedi; iki yaklaşım birlikte kullanıldığında ise anlamlı bir işlev artışı görüldü. Sonucu özel kılan tamamlayıcı etkidir; doğru cevap E’dir.

In the patient-derived organoid, CFTR function improved significantly only when the engineered sup-tRNA was paired with Trikafta.

Öbür parşömenler

Bütün parşömenler → · Bugünün parşömenlerini atölyede çöz →